A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

Young patients to meet dog with a difference at emergency services event

Description
Young patients will get to meet a dog with a difference tomorrow (Friday) as the emergency services descend on Southampton Children's
Url
/AboutTheTrust/Newsandpublications/Latestnews/2017/August-2017/Young-patients-to-meet-dog-with-a-difference-at-emergency-services-event.aspx

Rituximab (12 weekly)

Description
Chemotherapy Protocol LYMPHOMA RITUXIMAB (12 weekly) Regimen Lymphoma – Rituximab (12 Weekly) Indication Non- Hodgkin’s Ly
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Rituximab-12-weekly.pdf

Cisplatin Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (Oral) Regimen Ovary-Cisplatin-Etoposide PO Indicatio
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Ovarian-cancer/CisplatinEtoposidePO.pdf

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Uterine-Cisplatin-Etoposide
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Uterine-cancer/CisplatinEtoposidePO.pdf

Cisplatin and Etoposide PO

Description
Chemotherapy Protocol GYNAECOLOGICAL CANCER CISPLATIN-ETOPOSIDE (oral) Regimen Cervix-Cisplatin-Etoposide PO Indication Treatment of partially platinum-sensitive or platinum-refractory relapsed ovarian cancer. Small cell gynaecological cancers including those affecting the cervix, endometrium and ovaries. WHO performance status 0, 1, 2 Toxicity Drug Cisplatin Etoposide Adverse Effect Neuropathy, nephrotoxicity, ototoxicity Alopecia, hyperbilirubineamia The adverse effects listed are not exhaustive. Please refer to the relevant Summary of Product Characteristics for full details. Monitoring Drugs FBC, U&Es and LFTs prior to days 1, 8, 15 of treatment EDTA or calculated creatinine clearance prior to day 1 of each cycle CA125 prior to day 1 of each cycle Consider formal audiology testing Dose Modifications The dose modifications listed are for haematological, liver and renal function and drug specific toxicities only. Dose adjustments may be necessary for other toxicities as well. Version 1.1 (March 2014) Page 1 of 7 Cervix-Cisplatin-Etoposide PO In principle all dose reductions due to adverse drug reactions should not be re-escalated in subsequent cycles without consultant approval. It is also a general rule for chemotherapy that if a third dose reduction is necessary treatment should be stopped. Please discuss all dose reductions / delays with the relevant consultant before prescribing, if appropriate. The approach may be different depending on the clinical circumstances. Haematological Consider blood transfusion if patient symptomatic of anaemia or has a haemoglobin of less than 8g/dL. Prior to Cycle 1 the following criteria must be met; Criteria Neutrophil Platelets Eligible Level equal to or more than 1x109/L equal to or more than 100x109/L Day 1 - Dose modifications Neutrophils (x109/L) 1 or greater less than 1 Platelets (x109/L) 100 or greater less than 100 Dose Modifications (cisplatin and etoposide) 100% Delay treatment for 7 days. If resolved to 1x109/L or greater after 7 days continue at the full dose Dose Modifications (cisplatin and etoposide) 100% Delay treatment for 7 days. If resolved to 100x109/L or greater after 7 days continue at the full dose Day 8 and 15 - Dose modifications Neutrophils (x109/L) 1 or greater Dose Modifications (cisplatin and etoposide) 100% less than 1 Platelets (x109/L) 50 or greater Delay the cisplatin and and stop the etoposide Dose Modifications (cisplatin and etoposide) 100% less than 50 Delay the cisplatin and stop the etoposide Version 1.1 (March 2014) Page 2 of 7 Cervix-Cisplatin-Etoposide PO Hepatic Impairment Drug Cisplatin Bilirubin (μmol/L) N/A AST/ALT units N/A Dose (%of original dose) No dose adjustment needed Etoposide 26-51 or 51 or greater or 60-180 180 or greater Consider reducing course length Clinical decision Renal Impairment Drug Cisplatin Creatinine Clearance (ml/min) 60 or greater 45-59 less than 45 Dose (% of original dose) 100% 75% Consider alternative Etoposide 50 or greater 15-50 less than 15 100% 75% 50% Other Dose reductions or interruptions in therapy are not necessary for those toxicities that are considered unlikely to be serious or life threatening. For example, alopecia, altered taste or nail changes. For all other non-haematological NCI-CTC grade 3 and above toxicities delay treatment until the adverse effect has resolved to NCI-CTC grade 1 or below. The dose of the causative agent should then be reduced to 75% of the original dose or discontinued as appropriate. Regimen 28 day cycle for 2 cycles Drug Cisplatin Etoposide Dose 50mg/m2 50mg (flat dose) Days 1, 8, 15 1-14 incl. Administration Intravenous infusion in 1000ml sodium chloride 0.9% with 20mmol potassium chloride at a rate of 1mg/min cisplatin (minimum 120 minutes) Oral Followed by: Version 1.1 (March 2014) Page 3 of 7 Cervix-Cisplatin-Etoposide PO 28 day cycle for 6 to 9 cycles (six cycles will be set in Aria) Drug Etoposide Dose Days 50mg (flat dose) 1-21 incl. Oral Administration Dose Information Cisplatin will be dose banded according to the CSCCN agreed bands. Administration Information Extravasation Cisplatin – exfoliant Other Etoposide to be taken an hour before food or on an empty stomach Additional Therapy Antiemetics cycle one and two 15-30 minutes prior to chemotherapy cycle one and two only - aprepitant 125mg oral - dexamethasone 4mg oral or intravenous - ondansetron 8mg oral or intravenous As take home medication – Day 1, 8, 15 cycle one and two - aprepitant 80mg oral once a day for 2 days (Days 2 & 3) - dexamethasone 4mg oral once a day for 3 days - metoclopramide 10mg oral three times a day as required (Cycle 1 only) - ondansetron 8mg oral twice a day for 3 days Cisplatin pre and post hydration as follows; Pre Furosemide 40mg oral or intravenous 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes Version 1.1 (March 2014) Page 4 of 7 Cervix-Cisplatin-Etoposide PO Post 1000ml sodium chloride 0.9% with 20mmol potassium chloride and 16mmol magnesium sulphate over 60 minutes Patients should be advised to drink at least 3 litres of fluid in the 24 hours after administration of cisplatin. Gastric protection with a proton pump inhibitor or a H2 antagonist may be considered in patients considered at high risk of GI ulceration or bleed. Additional Information The National Patient Safety Alert on oral chemotherapy (NPSA/2008/RRR001) must be followed in relation to etoposide. Coding (OPCS 14-15) Procurement – X70.2 Delivery – X72.1 References 1. van der Burg M, de Wit R, van Putten W et al. Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer. Br J Cancer 2002; 86 (1): 19–25. 2. Meyer T, Nelstrop AE, Mahmoudi M et al. Weekly cisplatin and oral etoposide as treatment for relapsed epithelial ovarian cancer. Ann Oncol. 2001; 12 (12): 1705-9. Version 1.1 (March 2014) Page 5 of 7 Cervix-Cisplatin-Etoposide PO REGIMEN SUMMARY Cisplatin-Etoposide PO Cycles One and Two Day 1, 8, 15 1. Aprepitant 125mg oral 2. Dexamethasone 4mg oral or intravenous 3. Ondansetron 8mg oral or intravenous 4. Furosemide 40mg oral or intravenous 5. Sodium chloride 0.9% 1000ml with magnesium sulphate 16mmol and potassium chloride 20mmol intravenous infusion over 60 minutes 6. Cisplatin 50mg/m2 in 1000ml sodium chloride 0.9% with 20mmol potassium chloride intravenous infusion at a rate of 1mg/min cisplatin (minimum 120 minutes) 7. Sodium chloride 0.9% 1000ml with magnesium sulphate 16mmol and potassium chloride 20mmol intravenous infusion over 60 minutes Take Home Medicines 8. Etoposide 50mg oral once a day for 14 days 9. Aprepitant 80mg oral once a day for 2 days starting the day after intravenous chemotherapy Administration Instructions Please supply sufficient quantities for days 1, 8, 15 of the cycle 10. Dexamethasone 4mg oral once a day for 3 days starting the day after intravenous chemotherapy Administration Instructions Please supply sufficient quantities for days 1, 8, 15 of the cycle 11. Metoclopramide 10mg oral three times a day when required for nausea Administration Instructions Please supply 60 tablets or appropriate equivalent 12. Ondansetron 8mg oral twice a day for 3 days starting on the evening of intravenous chemotherapy Administration Instructions Please supply sufficient quantities for days 1, 8, 15 of the cycle Cycle Three, Four, Five, Six, Seven and Eight Day 1 – Take Home Medicines 13. Etoposide 50mg oral once a day for 21 days Version 1.1 (March 2014) Page 6 of 7 Cervix-Cisplatin-Etoposide PO DOCUMENT CONTROL Version 1.1 Date March 2014 Amendment PO added to name Bolus removed from “intravenous bolus”. Once daily changed to “once a day”. OPCS codes updated Metoclopramide dose changed to 10mg from 10-20mg. Disclaimer added 1 May 2013 None Written By Dr Deborah Wright Pharmacist Rebecca Wills Pharmacist Dr Deborah Wright Pharmacist Approved By Donna Kimber Pharmacy Technician Dr Clare Green Consultant Medical Oncologist Dr Cheng Yeoh Consultant Medical Oncologist This chemotherapy protocol has been developed as part of the chemotherapy electronic prescribing project. This was and remains a collaborative project that originated from the former CSCCN. These documents have been approved on behalf of the following Trusts; Hampshire Hospitals NHS Foundation Trust NHS Isle of Wight Portsmouth Hospitals NHS Trust Salisbury Hospital NHS Foundation Trust University Hospital Southampton NHS Foundation Trust Western Sussex Hospitals NHS Foundation Trust All actions have been taken to ensure these protocols are correct. However, no responsibility can be taken for errors which occur as a result of following these guidelines. Version 1.1 (March 2014) Page 7 of 7 Cervix-Cisplatin-Etoposide PO
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Cervical-cancer/CisplatinandEtoposidePO.pdf

Press release: Southampton surgeon helps create 'IKEA clinic' for global health disasters

Description
A Southampton surgeon has helped to develop a flat-pack health clinic – dubbed "IKEA for emergencies" – for use in global conflict and disaster zones.
Url
/AboutTheTrust/Newsandpublications/Latestnews/2019/March/Press-release-Southampton-surgeon-helps-create-IKEA-clinic-for-global-health-disasters.aspx

DH IVIg approved indications full guidance July 2011

Description
DH INFORMATION READER BOX Policy HR / Workforce Management Planning / Clinical Performance Document Purpose Gateway Reference Title Author Publication Date Target Audienc
Url
/Media/SUHTExtranet/TrustMedicinesFormulary/Forms/DH-IVIg-approved-indications-Full-Guidance-July-2011.pdf

EC-PPH Cyclophosphamide Epirubicin Paclitaxel Pertuzumab Trastuzumab

Description
Chemotherapy Protocol BREAST CANCER CYCLOPHOSPHAMIDE-EPIRUBICIN-PACLITAXEL-PERTUZUMABTRASTUZUMAB (EC-PPH)
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-PPH-Cyclophosphamide-Epirubicin-Paclitaxel-Pertuzumab-Trastuzumab.pdf

EC-DPH IV (Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab IV)

Description
Please refer to the most up to date Bluteq eligibility criteria for pertuzumab and trastuzumab before prescribing.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/EC-DPH-IV-Cyclophosphamide-Epirubicin-Docetaxel-Pertuzumab-Trastuzumab-IV.pdf

Papers Council of Governors - 27 April 2022

Description
Date Time Location Chair Agenda Council of Governors 27/04/2022 14:00 - 16:00 Microsoft Teams Jane Bailey 1 Chair’s Welcome and Opening C
Url
/Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2022-Trust-documents/Papers-Council-of-Governors-27-April-2022.pdf
1 to 10 of 54
Previous 1 2 3 4 5 … Next